Relevance of Ultraviolet-induced N-ras Oncogene Point Mutations in Development of Primary Human Cutaneous Melanoma
Overview
Authors
Affiliations
Intermittent or recreational exposure to sunlight is thought to contribute to development of human cutaneous melanoma. We investigated the incidence of ras oncogene mutation in human cutaneous melanoma in connection to sun-exposed body sites in the patient, using a large series of DNA samples derived from paraffin-embedded material as well as from fresh tumor samples and cell lines. We first show that, of the ras family, predominantly N-ras is activated (15%), whereas rarely H-ras or K-ras are mutated. The occurrence of N-ras mutations correlates with continuous exposure to sunlight of the primary tumor site. Of all tumors initiated on chronically sun-exposed body sites, 26% contained mutated N-ras, in contrast to 0% of sun-protected melanomas. Melanoma lesions obtained from patients from North or Central Europe contained fewer N-ras mutations (12%) as compared with patients from Australia (24%). Mutations were specifically associated with nodular melanoma and to a lesser extent with lentigo malignant melanoma. N-ras mutations did not correlate with metastasis or survival parameters. This study identifies a subset of cutaneous melanomas that contain in the primary lesion ultraviolet-induced N-ras mutations, which are maintained through further progression.
Longakit A, Urtatiz O, Luty A, Zhang C, Hess C, Yoo A Cancer Res Commun. 2025; 5(2):209-225.
PMID: 39804140 PMC: 11788999. DOI: 10.1158/2767-9764.CRC-24-0386.
De novo identification of expressed cancer somatic mutations from single-cell RNA sequencing data.
Zhang T, Jia H, Song T, Lv L, Gulhan D, Wang H Genome Med. 2023; 15(1):115.
PMID: 38111063 PMC: 10726641. DOI: 10.1186/s13073-023-01269-1.
Oxidative-Stress-Sensitive microRNAs in UV-Promoted Development of Melanoma.
Pecorelli A, Valacchi G Cancers (Basel). 2022; 14(13).
PMID: 35804995 PMC: 9265047. DOI: 10.3390/cancers14133224.
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.
Zhao J, Galvez C, Beckermann K, Johnson D, Sosman J Expert Rev Precis Med Drug Dev. 2021; 6(4):281-294.
PMID: 34485698 PMC: 8415440. DOI: 10.1080/23808993.2021.1938545.
Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai Y, Ke L, Zhang W, Lu J, Chen Y BMC Cancer. 2021; 21(1):677.
PMID: 34102999 PMC: 8185938. DOI: 10.1186/s12885-021-08427-x.